{'fraction_non_alphanumeric': 0.042977743668457406, 'fraction_numerical': 0.02686108979278588, 'mean_word_length': 5.150943396226415, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 19611: An Examination of Survival by Sex in the HVAD BTT and CAP Trials

Background: The HeartWare ® Ventricular Assist System (HVAD) is a novel design, continuous flow, centrifugal pump. The ADVANCE Bridge to Transplant Trial (BTT) was a multi-center, prospective trial that used an external contemporaneous control group from the Inter-Agency Registry for Mechanically Assisted Circulatory Support (INTERMACS) to compare the HVAD Pump with commercially available left ventricular assist devices (LVAD). Methods: Baseline characteristics, adverse events and subsequent survival were compared for men and women in the combined BTT and Continued Access Protocol trials (CAP). Survival was evaluated by Kaplan-Meier and proportional-hazards methodologies. Results: In the combined BTT and CAP study (N=332), 236 men and 96 women received an HVAD pump. At baseline, men had larger BSA (2.13+0.26 versus 1.80+0.25, P P =0.048) and more ischemic cardiomyopathy (45.3% versus 15.6%, P Conclusion: As expected, heart failure etiology differed between men and women in this BTT cohort. However, these data suggest that gender was not a factor for survival in men and women receiving the HeartWare System, and the survival data in women compares very favorably to data reported using contemporary LVADs.